Refractive Outcomes After Immediate Sequential vs Delayed Sequential Bilateral Cataract Surgery

Importance: Approximately 2 million cataract operations are performed annually in the US, and patterns of cataract surgery delivery are changing to meet the increasing demand. Therefore, a comparative analysis of visual acuity outcomes after immediate sequential bilateral cataract surgery (ISBCS) vs delayed sequential bilateral cataract surgery (DSBCS) is important for informing future best practices.

Objective: To compare refractive outcomes of patients who underwent ISBCS, short-interval (1-14 days between operations) DSBCS (DSBCS-14), and long-interval (15-90 days) DSBCS (DSBCS-90) procedures.

Design, Setting, and Participants: This retrospective cohort study used population-based data from the American Academy of Ophthalmology Intelligent Research in Sight (IRIS) Registry. A total of 1 824 196 IRIS Registry participants with bilateral visual acuity measurements who underwent bilateral cataract surgery were assessed.

Exposures: Participants were divided into 3 groups (DSBCS-90, DSBCS-14, and ISBCS groups) based on the timing of the second eye surgery. Univariable and multivariable linear regression models were used to analyze the refractive outcomes of the first and second surgery eye.

Main Outcomes and Measures: Mean postoperative uncorrected visual acuity (UCVA) and best-corrected visual acuity (BCVA) after cataract surgery.

Results: This study analyzed data from 1 824 196 patients undergoing bilateral cataract surgery (mean [SD] age for those <87 years, 70.03 [7.77]; 684 916 [37.5%] male). Compared with the DSBCS-90 group, after age, self-reported race, insurance status, history of age-related macular degeneration, diabetic retinopathy, and glaucoma were controlled for, the UCVA of the first surgical eye was higher by 0.41 (95% CI, 0.36-0.45; P < .001) letters, and the BCVA was higher by 0.89 (95% CI, 0.86-0.92; P < .001) letters in the DSBCS-14 group, whereas in the ISBCS group, the UCVA was lower by 2.79 (95% CI, -2.95 to -2.63; P < .001) letters and the BCVA by 1.64 (95% CI, -1.74 to -1.53; P < .001) letters. Similarly, compared with the DSBCS-90 group for the second eye, in the DSBCS-14 group, the UCVA was higher by 0.79 (95% CI, 0.74-0.83; P < .001) letters and the BCVA by 0.48 (95% CI, 0.45-0.51; P < .001) letters, whereas in the ISBCS group, the UCVA was lower by -1.67 (95% CI, -1.83 to -1.51; P < .001) letters and the BCVA by -1.88 (95% CI, -1.98 to -1.78; P < .001) letters.

Conclusions and Relevance: The results of this cohort study of patients in the IRIS Registry suggest that compared with DSBCS-14 or DSBCS-90, ISBCS is associated with worse visual outcomes, which may or may not be clinically relevant, depending on patients' additional risk factors. Nonrandom surgery group assignment, confounding factors, and large sample size could account for the small but statistically significant differences noted. Further studies are warranted to determine whether these factors should be considered clinically relevant when counseling patients before cataract surgery.

Errataetall:

CommentIn: JAMA Ophthalmol. 2021 Aug 1;139(8):885-886. - PMID 34196650

Medienart:

E-Artikel

Erscheinungsjahr:

2021

Erschienen:

2021

Enthalten in:

Zur Gesamtaufnahme - volume:139

Enthalten in:

JAMA ophthalmology - 139(2021), 8 vom: 01. Aug., Seite 876-885

Sprache:

Englisch

Beteiligte Personen:

Owen, Julia P [VerfasserIn]
Blazes, Marian [VerfasserIn]
Lacy, Megan [VerfasserIn]
Yanagihara, Ryan T [VerfasserIn]
Van Gelder, Russell N [VerfasserIn]
Lee, Aaron Y [VerfasserIn]
Lee, Cecilia S [VerfasserIn]
IRIS Research Analytic Center Consortium [VerfasserIn]
Last Name, First Name And Middle Initial S [Sonstige Person]
Lum, Flora [Sonstige Person]
Haller, Julia A [Sonstige Person]
Hyman, Leslie G [Sonstige Person]
Lorch, Alice C [Sonstige Person]
Miller, Joan W [Sonstige Person]
Pershing, Suzann [Sonstige Person]

Links:

Volltext

Themen:

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Anmerkungen:

Date Completed 20.04.2022

Date Revised 16.07.2022

published: Print

CommentIn: JAMA Ophthalmol. 2021 Aug 1;139(8):885-886. - PMID 34196650

Citation Status MEDLINE

doi:

10.1001/jamaophthalmol.2021.2032

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM327434023